Minimal efficacy of nitisinone treatment in a novel mouse model of oculocutaneous albinism, type 3

Ighovie F. Onojafe, Lucyanne H. Megan, Madeline G. Melch, Joseph O. Aderemi, Ramakrishna P. Alur, Mones S. Abu-Asab, Chi Chao Chan, Isa M. Bernardini, Jessica S. Albert, Tiziana Cogliati, David R. Adams, Brian P. Brooks

Research output: Contribution to journalArticle

Abstract

PURPOSE. Oral nitisinone has been shown to increase fur and ocular pigmentation in a mouse model of oculocutaneous albinism (OCA) due to hypomorphic mutations in tyrosinase (TYR), OCA1B. This study determines if nitisinone can improve ocular and/or fur pigmentation in a mouse model of OCA type 3 (OCA3), caused by mutation of the tyrosinase-related protein 1 (Tyrp1) gene. METHODS. Mice homozygous for a null allele in the Tyrp1 gene (C57BL/6J-Tyrp1b-J /J) were treated with 8 mg/kg nitisinone or vehicle every other day by oral gavage. Changes in fur and ocular melanin pigmentation were monitored. Mature ocular melanosome number and size were quantified in pigmented ocular structures by electron microscopy. RESULTS. C57BL/6J-Tyrp1b-J /J mice carry a novel c.403T>A; 404delG mutation in Tyrp1, predicted to result in premature truncation of the TYRP1 protein. Nitisinone treatment resulted in an approximately 7-fold increase in plasma tyrosine concentrations without overt toxicity. After 1 month of treatment, no change in the color of fur or pigmented ocular structures was observed. The distribution of melanosome cross-sectional area was unchanged in ocular tissues. There was no significant difference in the number of pigmented melanosomes in the RPE/choroid of nitisinone-treated and control groups. However, there was a significant difference in the number of pigmented melanosomes in the iris. CONCLUSIONS. Treatment of a mouse model of OCA3 with oral nitisinone did not have a favorable clinical effect on melanin production and minimally affected the number of pigmented melanosomes in the iris stroma. As such, treatment of OCA3 patients with nitisinone is unlikely to be therapeutic.

Original languageEnglish (US)
Pages (from-to)4945-4952
Number of pages8
JournalInvestigative Ophthalmology and Visual Science
Volume59
Issue number12
DOIs
StatePublished - Oct 2018

Keywords

  • Albinism
  • Retinal pigment epithelium
  • Visual acuity

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'Minimal efficacy of nitisinone treatment in a novel mouse model of oculocutaneous albinism, type 3'. Together they form a unique fingerprint.

  • Cite this

    Onojafe, I. F., Megan, L. H., Melch, M. G., Aderemi, J. O., Alur, R. P., Abu-Asab, M. S., Chan, C. C., Bernardini, I. M., Albert, J. S., Cogliati, T., Adams, D. R., & Brooks, B. P. (2018). Minimal efficacy of nitisinone treatment in a novel mouse model of oculocutaneous albinism, type 3. Investigative Ophthalmology and Visual Science, 59(12), 4945-4952. https://doi.org/10.1167/iovs.16-20293